Mesa Biotech to Present Research at Association for Molecular Pathology 2017 Annual Meeting
SAN DIEGO, CA – November 1, 2017 – Mesa Biotech, Inc., a privately-held, molecular diagnostic company that has developed an affordable PCR testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced that it will present original research at the annual Association for Molecular Pathology (AMP) meeting, being held November 16 – 18, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah.
Presentation Title: Comparison of the AcculaÔ Influenza A/B PCR Assay and AlereÔ Influenza A/B Isotherm Amplification Assay for the Detection of Influenza in Adult and Pediatric Populations
Speaker: Dr. Steve Young, Director of Research and Clinical Trials, TriCore Reference Laboratory
Time: November 18, 9:45 am – 10:45 am
Place: Exhibit Hall
Poster Number: ID25
“Our new technology aligns nicely with this year’s AMP Conference theme ‘Where Molecular Leads Medicine to Best Patient Care,” said Dr. Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. “We are excited to present our latest findings and research affirming the value of our first molecular PCR assay for use at the point of care for enhanced patient care.”
The AMP conference is a four-day event attended by clinical practitioners/physicians, research scientists, medical education professionals, laboratory professionals and students with an interest in diagnostic, prognostic, and therapeutic approaches in molecular pathology. The conference features cutting-edge lectures and discussions, corporate-sponsored workshops and plenary sessions focusing on major areas of clinical molecular diagnostics.
About Mesa Biotech Inc.
Mesa Biotech designs, develops and manufactures next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC). Mesa Biotech’s Accula™ System consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to access actionable, laboratory-quality results at the POC with greater sensitivity and specificity than current infectious disease rapid immunodiagnostic tests. Mesa Biotech’s technology development has been funded to date by a series of grants and private equity investments. For more information visit http://www.mesabiotech.com.
Follow the full story here: https://przen.com/pr/32091838